J. Goldman & Co’s Praxis Precision Medicines PRAX Stock Holding History

J. Goldman & Co’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.05M	Buy	15,664 +10,114	+182%	+$3.13M	0.15%	187
2025 Q4	$1.64M	Buy	+5,550	New	+$1.03M	0.04%	341
2025 Q1	–	Sell	-11,634	Closed	-$895K	–	596
2024 Q4	$895K	Buy	+11,634	New	+$842K	0.02%	334
2024 Q2	–	Sell	-12,336	Closed	-$753K	–	558
2024 Q1	$753K	Sell	12,336 -5,664	-31%	-$254K	0.02%	293
2023 Q4	$401K	Hold	18,000	–	–	0.02%	273
2023 Q3	$462K	Hold	18,000	–	–	0.02%	280
2023 Q2	$311K	Buy	18,000 +9,000	+100%	+$138K	0.01%	309
2023 Q1	$109K	Buy	+9,000	New	+$380K	﹤0.01%	330

Other funds holding PRAX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

J. Goldman & Co's PRAX Position: Q1 2026 in Review

J. Goldman & Co increased its Praxis Precision Medicines (PRAX) stake by 182% in Q1 2026, buying an estimated $3.13M and bringing the position to 15,664 shares worth $5.05M. The position accounts for 0.15% of the portfolio, ranked #187.

J. Goldman & Co first reported a position in PRAX in Q1 2023 and has held it in 8 quarters since. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

J. Goldman & Co held 15,664 shares of Praxis Precision Medicines worth $5.05M as of Q1 2026.
J. Goldman & Co bought 10,114 Praxis Precision Medicines shares in Q1 2026, an estimated $3.13M.
Praxis Precision Medicines made up 0.15% of J. Goldman & Co's portfolio in Q1 2026, its #187 holding.
J. Goldman & Co first reported a position in Praxis Precision Medicines in Q1 2023 and has held it in 8 quarters since.
289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.